{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kang YM"],"funding":["Yin Shu-Tien Foundation Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation","Ministry of Education, Culture, Sports, Science and Technology of Japan"],"pagination":["1540-1551"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9883571"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(2)"],"pubmed_abstract":["<h4>Background</h4>To evaluate the clinical relative biological effectiveness (RBE) of carbon-ion radiotherapy (C-ion RT) for prostate cancer.<h4>Methods</h4>The records of 262 patients with low-risk prostate cancer (median age, 65 [47-80] years) treated with C-ion RT at QST Hospital, National Institutes for Quantum Science and Technology in Japan during 2000-2018 were reviewed retrospectively. Four different protocol outcomes and prostate-specific antigen (PSA) responses were evaluated. The median follow-up was 8.4 years. The Kaplan-Meier method was used to estimate the biochemical or clinical failure-free rate (BCFFR). Clinical RBE was calculated using the tumor control probability model.<h4>Results</h4>The 5-, 7-, and 10-year BCFFRs were 91.7%, 83.8%, and 73.2%, respectively. The 10-yea"],"journal":["Cancer medicine"],"pubmed_title":["The clinical relative biological effectiveness and prostate-specific antigen kinetics of carbon-ion radiotherapy in low-risk prostate cancer."],"pmcid":["PMC9883571"],"funding_grant_id":["21K0771","109-V-A-008"],"pubmed_authors":["Inaniwa T","Liu YM","Tsujii H","Kang YM","Iwai Y","Okonogi N","Tsuji H","Chao Y","Kasuya G","Wakatsuki M","Matsufuji N","Ishikawa H"],"additional_accession":[]},"is_claimable":false,"name":"The clinical relative biological effectiveness and prostate-specific antigen kinetics of carbon-ion radiotherapy in low-risk prostate cancer.","description":"<h4>Background</h4>To evaluate the clinical relative biological effectiveness (RBE) of carbon-ion radiotherapy (C-ion RT) for prostate cancer.<h4>Methods</h4>The records of 262 patients with low-risk prostate cancer (median age, 65 [47-80] years) treated with C-ion RT at QST Hospital, National Institutes for Quantum Science and Technology in Japan during 2000-2018 were reviewed retrospectively. Four different protocol outcomes and prostate-specific antigen (PSA) responses were evaluated. The median follow-up was 8.4 years. The Kaplan-Meier method was used to estimate the biochemical or clinical failure-free rate (BCFFR). Clinical RBE was calculated using the tumor control probability model.<h4>Results</h4>The 5-, 7-, and 10-year BCFFRs were 91.7%, 83.8%, and 73.2%, respectively. The 10-yea","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-05T09:03:13.78Z","creation":"2025-04-05T09:03:13.78Z"},"accession":"S-EPMC9883571","cross_references":{"pubmed":["35852142"],"doi":["10.1002/cam4.5045"]}}